Through this study, the authors sought to investigate the biologic and immunologic effects of preoperative trastuzumab in patients with ductal carcinoma in situ (DCIS) of the breast.
Through this study, the authors sought to investigate the biologic and immunologic effects of preoperative trastuzumab in patients with ductal carcinoma in situ (DCIS) of the breast.
Patients with DCIS were enrolled in this open-label phase 2 trial and tested for HER2. Trastuzumab was given by intravenous infusion (8 mg/kg). The patients then had surgery 14 to 28 days after treatment. Tissue and peripheral blood samples were obtained before therapy and at the time of surgery to examine residual disease and immunologic response.
Median age of the 69 enrolled patients was 53 years, mean mammographic size of the DCIS lesions was 5.2 ± 1.2 cm, and 24 patients (35%) were found to have HER2 overexpression/amplification (12 received trastuzumab and 12 untreated patients provided tissue for blinded, controlled biomarker analyses). No overt histologic evidence of response was noted. No significant change in mean pretherapy staining for Ki-67 (44.3 ± 3.4%) and cleaved caspase-3 (2.6 ± 0.8%) was noted when surgical specimens from drug-treated patient samples were compared with those not treated. Trastuzumab significantly augmented antibody-dependent cell mediated cytotoxicity (ADCC) in 100% of patients; this was demonstrated to be mediated through CD56+ degranulating natural killer cells (P < .01). One patient developed a significant anti-HER2 humoral CD4 T-cell response.
Single-dose monotherapy with trastuzumab for patients with HER2-positive DCIS does not result in significant, clinically overt, histologic, antiproliferative, or apoptotic changes, but does result in the ability to mount ADCC mediated through natural killer cells and may also induce T-cell dependent humoral immunity. Further studies of trastuzumab for DCIS appear warranted. Cancer 2011. © 2010 American Cancer Society.
Ductal carcinoma in situ (DCIS) is the fourth leading cause of cancer among women in the United States, with approximately 64,000 cases diagnosed annually.1 There is a critical need for the development and investigation of agents that can either eradicate DCIS, thereby averting surgery and radiation, or prevent frankly invasive disease in most patients.
Several lines of evidence suggest the logic in studying trastuzumab, a monoclonal antibody targeting HER2/neu (HER2), for the treatment of DCIS. Neoadjuvant trastuzumab may be able to prevent the development of invasive breast cancer in patients with DCIS in much the same way that tamoxifen markedly decreases the risk of breast cancer development in women with high-risk proliferative lesions such as atypical ductal hyperplasia.2 A further rationale for studying neoadjuvant trastuzumab for DCIS relates to the scarcity of effective medical treatments for estrogen receptor (ER)-negative DCIS. Additional support for studying the efficacy of trastuzumab against DCIS comes from promising results from trials of neoadjuvant trastuzumab for invasive breast cancer. Gennari et al showed that administration of a short, preoperative course of single-agent trastuzumab to 11 patients with early stage invasive breast cancer resulted in a complete pathologic response in 1 patient and partial responses in 4.3 The in vivo mechanism of action of trastuzumab is not completely understood. In animal models the activity of trastuzumab is dependent on the engagement of Fc-receptor expressing lymphocytes, suggesting that ADCC is a major mechanism of action.4 Other investigators have demonstrated development of a T-cell dependent humoral response.5 We hypothesized that trastuzumab would have substantial activity against DCIS, perhaps even more than it has against invasive breast cancer, because the volume of disease in DCIS patients is normally much lower. This study is the first prospective trial of neoadjuvant trastuzumab in patients diagnosed with DCIS that overexpresses HER2 to test this hypothesis and to study individual patients' immune responses with therapy to elucidate potential mechanisms of trastuzumab activity. This trial utilized a blinded controlled analysis of selected biomarkers in treated cases before and after therapy and in untreated patients with HER2-positive DCIS.
This study was a prospective, open-label, phase 2 trial approved by and conducted at The University of Texas M. D. Anderson Cancer Center between March 2005 and February 2009.
Patients with histologically confirmed DCIS showing measurable residual microcalcifications on mammography after initial diagnostic biopsy were counseled regarding the study. To be eligible, patients were required to have adequate bone marrow, renal, cardiac, and liver function, and women of childbearing potential were required to have a negative urine or serum pregnancy test. Eligible patients were required to give informed consent before testing their DCIS for HER2 status. Once consent was obtained, HER2 status was determined using immunohistochemical (IHC) analysis (AB8 Neomarkers; Labvision, Fremont, Calif) or fluorescence in situ hybridization (FISH; PathVysion assay kit; Vysis, Inc., Downers Grove, Ill). DCIS was considered to be positive if determined to be HER2 3+ by IHC or positive for HER2 gene amplification (HER2/CEP17 ratio >2.0) by FISH.
Patients with HER2-positive DCIS were eligible to receive the study drug. Trastuzumab was provided free of charge to all patients by Genentech, Inc. (South San Francisco, Calif). Trastuzumab was given at a dosage of 8 mg/kg over a 90-minute intravenous infusion, and patients were scheduled for surgery 14 to 28 days after treatment. Surgical procedures were dictated by the extent of disease and patient preference. Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria (version 3.0).
Processing was performed according to routine, clinical pathology tissue processing methods. IHC analyses for Ki-67, a nuclear marker for cell proliferation (Clone MIB-1, Dako, Glostrup, Denmark), and cleaved caspase-3 (Asp175), 1 of the key executioners of apoptosis (Cell Signaling Technology, Danvers, Mass), were performed in duplicate using residual formalin-fixed paraffin-embedded (FFPE) biopsy tissue sections that contained DCIS before treatment and from the corresponding FFPE tissues that contained DCIS from the surgical resection.
Tissue samples collected from enrolled patients with HER2 overexpression/amplification who gave informed consent to participate in the study, but did not receive study drug,because of surgical scheduling or patient preference, served as internal negative controls. All analyses were performed by investigators who were blinded to clinical information, including receipt or nonreceipt of study drug.
Peripheral blood collected with anticoagulant was used to isolate peripheral blood mononuclear cells (PBMC) by standard Ficoll gradient centrifugation (Accu-Prep Lymphocites, Oslo, Norway). After centrifugation, PBMCs were washed with medium containing 10% fetal bovine serum (FBS) and resuspended in 90% FBS+ 10% DMSO at a concentration of 10 × 106/mL.
Patient's PBMCs were tested for their killing capacity against a HER2-overexpressing target cell line (MDA-MB-361) in the presence of simultaneously harvested autologous serum. The MDA-MB-361 cell line was validated by STR DNA fingerprinting using the AmpFlSTR Identifiler Kit according to the manufacturer's instructions (Applied Biosystems, Foster City, Calif). ADCC by trastuzumab was measured in a 51Cr release assay using radiolabeled target cells from the HER2-overexpressing human breast cancer cell line MDA-MB-361. To this end, 1-3 million MDA-MB-361 target cells were labeled with 100 μCi (3.7 MBq) of Na51Cr (Perkin Elmer, Waltham, Mass) for 1 hour at 37°C, washed extensively, and used as targets. Five thousand 51Cr-labeled target cells per well were seeded into 96-well U-bottomed plates. Experiments were conducted in triplicate at PBMC (effector) to MDA-MB-361 (target) ratios of 12.5:1, 25:1, and 50:1, in 200 μL of RPMI 1640 containing 20% autologous human serum. The antibody source for evaluation of ADCC was made up of trastuzumab, autologous serum of treated patients, or both. Thus, all ADCC experiments were carried out in the presence of 20% autologous serum, with or without 10 μg/mL of trastuzumab (added exogenously). After 4 hours at 37°C in humidified air with 5% CO2, the release of 51Cr was determined by taking 100 μL of supernatant and counting using a Wizard 1470 Automate gamma counter (Perkin Elmer, Waltham, Mass). Maximal and spontaneous 51Cr release values were obtained by adding either 1 % Tween detergent (Fisher Scientific, Pittsburgh, PA) or complete medium, respectively, to microtiter wells containing 5 × 103 labeled target cells. The percentage of lysis was calculated according to the standard formula ((counts per minute experimental) – (counts per minute spontaneous release))/((counts per minute maximum release) – (counts per minute spontaneous release)) × 100.
An 8-parameter flow cytometric analysis of thawed PBMC was performed using a 3-laser FACSCanto II instrument equipped with DIVA software (BD Biosciences, San Jose, Calif). To identify phenotype modifications of effector lymphocytes involved in trastuzumab-mediated cytotoxicity, as well as the frequency of effector natural killer (NK) and T cell populations among PBMCs 4×105, the PBMCs prepared for use in the ADCC assay were left in parallel cultures with unlabeled MDA-MB-361 target cells at an effector-to-target ratio of 25:1 in the presence of 20% autologous serum, or trastuzumab (10 μg/mL), or in their absence (negative control), in otherwise identical culture conditions of ADCC assay. To test CD107a mobilization, anti-CD107a-Alexa Fluor 488-conjugated (mouse IgG1, H4A3, eBioscience, San Diego, Calif) was added at 1 μg/106 cells at the beginning of culture. One hour into the culture, GolgiStop was added (BD Pharmingen, San Diego, Calif) in accordance with manufacturer's instructions. At the end of culture (6 hours total), cells were harvested, washed, and directly stained with 1 μg/106 cells of each of the following mAbs: anti-CD3-PE (UCHT1, mouse IgG1), anti-CD56-APC (B159, mouse IgG1), anti-CD16-PECy7 (3G8, mouse IgG1), anti-CD69-APCCy7 (FN50, mouse IgG1), CD8-Pacific Blue (RPA-T8, mouse IgG1), CD4-PerCPCy5.5 (SK3, mouse IgG1) (all from BD Pharmingen, San Diego, Calif), and LIVE/DEAD Aqua Cell Stain (Invitrogen, Carlsbad, Calif) or with isotype-matched mAbs of irrelevant specificity or with isotype-matched mAbs. Cells were then fixed and analyzed within 24 hours.
Fourteen HER2-derived peptides, each known to bind to multiple HLA-DR molecules,5, 6 were used to detect T-cell responses by the enzyme-linked immunospot (ELISPOT) method.7 The peptides, which are designated by the position of the first amino acid (Pool I: p98, p369, p927; Pool II: p776, p62, p77; Pool III: p83, p88, p350; Pool IV: p976, p42, p688; and Pool V: p971, p1166) were all class II peptides that have been previously described.5, 6, 8, 9 Both phorbol 12-myristate 13-acetate/ionomycin and tetanus toxoid were used as positive controls. In brief, cryopreserved PBMCs were cultured at 2 × 105 cells per well in 96-well plates for 7 days in medium containing pools of HER2 peptides (pools of 2 or 3 peptides, each at 10 μg/mL) or with HIV peptide control (negative control). In these cases, all of the time points were assessed with the same panels of peptides. Interleukin-2 (10 U/mL) was added at Day 5. On Day 7, peptide and irradiated autologous PBMCs (2 × 105 per well) were added as antigen-presenting cells. On Day 8, the cells were gently transferred to the ELISPOT plate for detection of spots with a pair of IFNγ-specific antibodies (Mabtech, Mariemont, Ohio). ELISPOTs were developed, dried, and read with a C.T.L. Immunospot ELISPOT reader, using the programs Image Acquisition 4.4 and Immunospot 3 (Cellular Technology Ltd, Shaker Heights, Ohio). Peptide-specific immune reactivity was determined by subtracting the background spots in the HIV wells. A positive response was defined as peptide-specific spots that were statistically higher (triplicates) than control wells using a 2-tailed t test (P < .05). A zero response was assigned if the peptide-specific wells were not different from control wells. The counts for each peptide were summed and presented as the total HER2–specific T-cells per million PBMC, assessed at each time point.6
Nipple aspirate fluid was obtained from patient number 7 at the time of surgery as previously described.10 The fluid droplets were collected and centrifuged at 1500 RPM for 10 minutes, and the supernatant was stored at −80°C until measurement. Detection and quantification of trastuzumab in the ductal fluid were kindly performed by the laboratory of Dr. David Jamieson at Northern Institute for Cancer Research, University of Newcastle upon Tyne, using a cell-based ELISA assay that measures the interaction between trastuzumab and formalin-fixed HER2+ SKBR3 cells.11
Twelve evaluable patients were required to characterize the change in proliferation rate after treatment with a single dose of trastuzumab. To accrue 12 evaluable patients with DCIS, trastuzumab administration, surgery, and post surgery biomarkers testing, it was estimated that up to 71 patients needed to be registered in the study. A 6% absolute reduction in the proliferation rate, as measured by Ki-67, was designated as the study endpoint, providing sufficient preliminary data to pursue larger clinical studies with trastuzumab for DCIS. To compare ADCC and CD4+ T-cell response in each patient observed at pre- and post-treatment times, paired analysis was performed using Student t test. Nonparametric Wilcoxon rank sum test was used to compare data between groups. Statistical tests were performed with Prism 4 software (San Diego, Calif), and P < .05 was considered significant.
Sixty-nine patients were enrolled in the trial (median age, 53 years). Overall, 24 (35%) patients had lesions with overexpression or amplification of HER2. HER2-overexpression/amplification correlated with histologic grade and ER expression. Overall, 6% of patients had grade I, 38% had grade II, and 56% had grade III lesions. Patients with high-grade lesions were more likely to exhibit HER2-overexpression/amplification (0% grade I, 27% grade II, and 44% in grade III, respectively; P = .10). Overall, 81% of the DCIS cases were ER positive. HER2- overexpression/amplification was significantly more likely in ER negative versus ER positive DCIS (62% vs 28%, respectively; P = .047).
After receipt of HER2 testing results, 12 patients received study drug and 12 patients did not receive study drug, either because of surgical scheduling constraints or a final decision not to take the study drug after receiving the HER2 results.
On average, surgery was performed at 18.08±5.21 days after administration of trastuzumab. Patients receiving trastuzumab had large DCIS lesions with the mean mammographic extent of disease measuring 5.15 ± 1.15 cm. Mastectomy was performed in the majority of patients (n = 8 of 12) with immediate breast reconstruction in all but 1 patient. The mean final pathologic size of the DCIS for these 12 patients was 5.15 ± 3.73 cm. In addition to DCIS, 42% (n = 5) of the patients evidenced invasive breast cancer on their pathologic specimen. The mean size of invasive cancer in these patients was 0.28 cm; none of these patients was found to have sentinel lymph node metastases.
Three patients (25%) had an adverse event reported during the study period. Two patients experienced a grade I or II infusion reaction consisting of chills or chills and fever, which resolved with administration of diphenhydramine and acetaminophen or hydrocortisone and meperidine, respectively. One 49 year-old participant with a distant history of adult-onset seizure developed grade I right upper lip numbness 3 days after infusion of study drug, which resolved without further intervention. Complete neurologic workup was within normal limits.
Each of the 12 treated patients had residual DCIS at the time of surgery, without overt histopathologic evidence of response to treatment.
Pre- and post-treatment tissue with DCIS was studied for proliferation and apoptosis in patients treated with trastuzumab. Tissue from the additional 12 patients who did not receive study drug was evaluated as an internal control. The mean percent Ki-67 staining was 44.29 ± 3.42% and the mean percent cleaved caspase-3 staining was 2.59 ± 0.78% for DCIS tissue from all initial biopsy specimens. After administration of trastuzumab, Ki-67 staining increased on average by 16.11% and cleaved caspase-3 staining increased on average by 2.3%, as measured in tissue before and after treatment (Fig. 1). For patients not receiving study drug, Ki-67 staining increased on average by 17.23% and cleaved caspase-3 staining increased on average by 4.15% (Fig. 1). No significant differences were identified with respect to percent change in Ki-67 staining (P = .75) or cleaved caspase-3 staining (P = .65) between patients who did and did not receive trastuzumab.
To investigate the role of ADCC in patients with DCIS enrolled in this study, cell-mediated cytotoxic activity was evaluated ex vivo in 51Cr-release cytotoxicity assays using patient PBMCs in the presence of autologous serum versus HER2-overexpressing breast cancer target cells. As demonstrated in Figure 2, ADCC exerted by PBMC in the presence of autologous sera increased significantly for 9 of 9 (100%) patients tested where sufficient cells were available after the single dose of trastuzumab (P < .0035). Taking into account all evaluable patients, the increase was significant, but there was considerable heterogeneity in the response. These data confirm that trastuzumab was present in the serum of patients receiving the drug and suggest that ADCC may occur in vivo and contribute to trastuzumab's mechanism of action.
To identify the effector cells involved in trastuzumab-mediated cytotoxicity, flow cytometry was used to analyze the phenotype of lymphocytes cultured for the ADCC assay. Classical ADCC is mediated by NK cells; therefore, we focused the analysis on this population, defined as CD56+CD16±. As demonstrated in Figure 3A, which depicts 1 representative patient, after administration of trastuzumab there was increased expression of cell surface secreted CD107a, a molecule linked to the killing activity of cytotoxic lymphocytes. The percentage of CD56+CD107a+ degranulating NK cells was calculated by subtracting the percentage of CD56+CD107a+ using normal donor AB serum from the percentage of CD56+CD107a+ using autologous serum (Fig. 3B). For the patient depicted in Figure 3A, this increased from 0.41% to 5.28% after administration of trastuzumab. The data for all patients are depicted in Figure 3B, which demonstrates a significant increase in the percentage of CD56+CD107a+ degranulating NK cells for all 12 patients (100%) tested after the single dose of trastuzumab (P < .00005). These data suggest that ADCC induced by trastuzumab treatment in DCIS patients is mediated by degranulating CD56+ NK cells.
ELISPOT assays were used to determine CD4 T-cell responses against multiple HER2-derived class II peptides. The peptides were evaluated as pools and the composition of each of the 5 pools. There were 9 evaluable patients who had sufficient PBMC available pre- and post-treatment. The frequency of HER2 peptide-pool-specific T-cells for each patient is shown in Table 1. Table 1 depicts the pre- and post-treatment HER2-specific T-cell levels in the 9 patients with evaluable PBMC at both time points. Each point is the total CD4 T-cell frequency calculated by summing the counts for each peptide and subtracting out counts against the control peptide. Only 1 patient had a significant CD4 T-cell response (Pool II and V), suggesting that a single dose of trastuzumab did not promote a generalized T-cell dependent response in these patients with DCIS.
|Patient 3||Patient 4||Patient 5||Patient 7|
|Patient 8||Patient 9||Patient 10||Patient 11|
Before this publication, it was unknown whether trastuzumab could pass through the basement membrane or be secreted into the breast ducts in humans. In 1 treated patient, ductal fluids were obtained at the time of surgery on Day 18 after administration of trastuzumab. Trastuzumab was demonstrated to be present within the ducts at a level of 161 μg/mL.
This study is the first to report on the use of neoadjuvant trastuzumab for patients with HER2 positive DCIS. We have found that single dose monotherapy with trastuzumab for patients with HER2-positive DCIS does not result in significant, clinically overt histologic, anti-proliferative, or apoptotic changes, but does result in the specific ability to mount ADCC mediated through NK cells and may also induce humoral immunity in a T-cell dependent manner.
Before this study, it was not known what alterations in the histologic appearance might be seen using trastuzumab for DCIS. In the neoadjuvant setting for invasive cancer, histologic changes seen after administration of trastuzumab with chemotherapy can range from minimal effect to marked decreases in size and cellularity to complete eradication of any evidence of disease (complete pathologic response).12 After 1 cycle of trastuzumab given in the present study for DCIS, no particular morphologic changes were noted. Changes in proliferation (Ki-67) and apoptosis (cleaved caspase-3) were therefore investigated to better evaluate the tissue effects of a single dose of trastuzumab on DCIS. Compared with patients not receiving trastuzumab, there was no significant change in proliferation or apoptosis. Two previous studies enrolling patients with HER2-overexpressing invasive breast cancer have evaluated proliferation after short-course trastuzumab therapy. Mohsin et al evaluated a 3-week shortcourse of trastuzumab in patients with locally advanced invasive breast cancer and, consistent with our findings, noted no change in proliferation as measured by Ki-67.13 A second study by Gennari et al evaluated 11 patients that received a loading dose of trastuzumab followed by 3 weekly doses.3 They also noted no change in proliferation. These data are in contrast to in vitro data investigating potential mechanisms of action of trastuzumab in the laboratory. In vitro blockade of the HER2 receptor results in upregulation of the cell cycle inhibitor p27, which can inhibit cyclin E/cdk2 complexes and produce G1 cell cycle arrest, with a concomitant reduction in proliferation.14, 15
Despite not seeing a decrease in proliferation, Mohsin et al reported clinical responses evidenced by significant tumor regression.13 These authors performed additional studies to investigate the mechanism of this cytotoxic effect and were able to demonstrate a significant increase in apoptosis. These data are notable because, in in vitro models using cultured breast cancer cells, trastuzumab has not proven capable of inducing apoptosis.13 In the current study, we did not see evidence of increased apoptosis in DCIS patients treated with trastuzumab. Both our study and the one by Mohsin et al were investigating apoptosis in vivo and both used the same assay—suggesting the differences cannot be explained by methodology. It is likely that this difference derives from the fact the current study enrolled patients with noninvasive cancer, whereas the study by Mohsin et al enrolled patients with very large, advanced invasive tumors that were more susceptible to therapy. It is possible that longer treatment may be required to see changes in histology or biomarkers in patients with DCIS treated with trastuzumab.
These data also highlight the finding that the mechanism by which trastuzumab exerts its therapeutic action remains incompletely understood. Mechanisms of action of trastuzumab include inhibition of HER2 extracellular domain proteolysis, disruption of downstream signaling pathways, G1 cell-cycle arrest, inhibition of DNA repair, suppression of angiogenesis, and induction of ADCC.16, 17 One mechanism of action shown to be significant in vivo, first in a mouse model and then in the shortcourse trastuzumab trial conducted by Gennari et al, is ADCC.3, 18 Our data also demonstrated ADCC activity by PBMC obtained from patients treated with trastuzumab in the presence of autologous serum. This finding confirmed that there was trastuzumab in the serum of these patients, which is consistent with the known long half-life of this agent.11 It also confirmed that ADCC is a potential mechanism of action by which trastuzumab may exert cytotoxic activity. It is important to note, however, that these data are from an ex vivo assay and do not confirm that ADCC occurred in our patients. The finding that apoptosis, considered the final pathway for ADCC-mediated cytotoxicity, did not arise suggests that significant ADCC was not occurring in vivo in these patients.13
To further assess the immune response, we looked for evidence that HER2-specific immunity was being induced. In a study evaluating patients with HER2-overexpressing metastatic breast cancer treated with trastuzumab and chemotherapy, Taylor et al demonstrated a significant increase in the anti-HER2 humoral response associated with an increase in HER2-specific CD4+ T-cell responses.5 This suggests that the therapeutic antibody trastuzumab can not only provide passive immunotherapy through ADCC, but also induce active immunity by promoting a cellular response. In the current study, only 1 patient had a significant CD4+ T-cell response, suggesting that a single dose of trastuzumab does not promote a generalized T-cell response in most patients with DCIS.
As DCIS by pathologic definition remains within the breast ducts, it was of interest to determine whether trastuzumab could be detected within nonlactating human ductal fluids. Immunoglobulins are known to be secreted in the milk, and trastuzumab has been detected in milk of lactating monkeys given intravenous trastuzumab.19 In the current study, trastuzumab was shown, using a new cell-based ELISA for quantification of trastuzumab in human plasma,11 to cross the basement membrane in a nonlactating patient with DCIS and enter the breast ducts. The assay, developed and validated by Jamieson et al, specifically measures the interaction between trastuzumab and HER2.11 This is the first published study to demonstrate the presence of trastuzumab in human ductal fluids and show that trastuzumab can theoretically act on cancer cells located within the breast ducts.
Some clinicians have voiced concern that preoperative studies of DCIS run the risk of undertreating women who have a concurrent occult invasive breast cancer. In the current study, 45% of patients did, in fact, have an occult, small, invasive cancer detected in the surgical specimen. There was an inherent selection bias resulting from surgery scheduling issues in favor of enrolling patients with very large DCIS in the current study. Patients who were going to schedule a mastectomy with immediate reconstruction (87.5% of patients chose immediate reconstruction) were more likely to participate in the study than patients with much smaller DCIS who could be immediately scheduled for segmental resection. The average size of the DCIS was over 5 cm in this study, and it has been established that larger size is an independent risk factor for finding occult invasive cancer.20 Another potential selection bias for identification of occult invasive cancer in a high proportion of treated patients may involve the overexpression of HER2. In a recent study published by Roses et al, invasive disease was found in association with HER2-overexpressing DCIS at a higher frequency than with DCIS that did not overexpress HER2.21 Despite these legitimate concerns, the current study is important because we have demonstrated that a DCIS “window study” can be performed safely. It is likely that many similar preoperative trial designs will be utilized in future studies of DCIS. Missing an occult invasive malignancy is of concern, and it is anticipated that more stringent DCIS size eligibility criteria and the use of potentially better imaging will markedly decrease the risk of missing a concurrent occult invasive component.
Finally, the National Surgical Adjuvant Breast and Bowel Project (NSABP) is studying the potential efficacy and role of postoperative trastuzumab for DCIS in a phase 3 randomized trial for patients with DCIS treated with breast conservation surgery. Patients are being randomized to 6 weeks of whole-breast irradiation with or without concurrent trastuzumab, given in 2 doses at week 1 and 3. The rationale for using trastuzumab concurrently with radiation for HER2-overexpressing DCIS is that trastuzumab only radiosensitizes cells that overexpress HER2, and therefore will enhance the radiation sensitivity of carcinoma more than surrounding healthy tissues. The results of this study provide no evidence that trastuzumab utilized with radiation will or will not be effective. Furthermore, the NSABP study is also designed to evaluate the long-term potential effects of trastuzumab on the prevention of contralateral breast cancer.
In summary, this phase 2, open-label clinical trial using a single dose of intravenous trastuzumab for patients with HER2-positive DCIS did not result in significant, clinically overt histologic, anti-proliferative, or apoptotic changes, but did result in the specific ability of treated patients to mount ADCC mediated through NK cells and induce humoral immunity in a T-cell-dependent manner in 1 patient. These findings warrant additional studies to determine whether these short-term immune responses may prove useful in the prevention of recurrent or contralateral breast cancer.
Funding for the trial was provided by research grant funds received from Randalls Food Markets, Genentech, and NCI # CA16672.